Seung Suh Hong
Director/Board Member at OCULAR THERAPEUTIX, INC.
Net worth: 87 919 $ as of 29/04/2024
Profile
Seung Suh Hong's current job(s) include Vice Chairman at Novalgen Ltd., Vice Chairman at Novelgen Co. Ltd(South Korea), Independent Director at Ocular Therapeutix, Inc., and President & Chief Operating Officer at Cellemedy Co., Ltd.
.
Dr. Hong's former job(s) include President & Chief Executive Officer at Celltrion Healthcare Co., Ltd.
from 2002 to 2015, and President at Celltrion Healthcare Japan KK from 2016 to 2019.
Dr. Hong's education history includes undergraduate, graduate, and doctorate degrees from Seoul National University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0.01% | 13/06/2023 | 20,933 ( 0.01% ) | 87 919 $ | 29/04/2024 |
Seung Suh Hong active positions
| Companies | Position | Start |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Director/Board Member | 10/06/2019 |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | President | 31/12/2020 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Board Member | 31/12/2020 |
| Novelgen Co. Ltd(South Korea) | Director/Board Member | 31/03/2020 |
Former positions of Seung Suh Hong
| Companies | Position | End |
|---|---|---|
| Celltrion Healthcare Japan KK | President | 01/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Chief Executive Officer | 30/11/2015 |
Training of Seung Suh Hong
| Seoul National University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| CELLTRION HEALTHCARE CO., LTD. | Health Technology |
| Private companies | 4 |
|---|---|
| Celltrion Healthcare Japan KK | |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
| Novelgen Co. Ltd(South Korea) |
- Stock Market
- Insiders
- Seung Suh Hong
